Navigation Links
MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers
Date:12/2/2010

NOVATO, Calif., Dec. 2, 2010 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for BMN 673 for genetically-defined cancers.  The company expects to initiate a Phase 1/2 trial by the first quarter of 2011.

"BMN 673 has been proven to be highly active in mouse xenograft models of human cancer and appears to have superior potency, selectivity, and bioavailability as compared to other products in development," said Hank Fuchs, Chief Medical Officer of BioMarin.  "We are eager to get this trial underway and to identify specific tumor types that are more susceptible to treatment with BMN 673.  We have built a deep R&D pipeline and remain focused on successfully and expeditiously executing on the programs."

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking StatementThis press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of the development of BMN 673, including the timing of the clinical trials of the candidate, and the possible efficacy of such candidate. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities, results and timing of current and planned clinical and preclinical studies related to such product; our ability to successfully manufacture the product; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Eugenia ShenBioMarin Pharmaceutical Inc.(415) 506-6570
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arbor Pharmaceuticals Completes $34.8 Million Financing
2. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
3. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
4. Apollo Endosurgery Completes First-in-Human Cases With New OverStitch™ Endoscopic Suturing System
5. Boston Scientific Completes Acquisition of Asthmatx
6. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
7. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
8. Incept BioSystems Completes First Human Clinical Trial of the SMART Start™ Embryo Culture System and Submits 510(k) Application to the FDA
9. InfraReDx Completes $21 Million Equity Financing
10. Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
11. Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
(Date:9/7/2017)... RANCHO MIRAGE, Calif. , Sept. 7, 2017  For nearly two ... and service in the Assisted Reproduction Insurance industry. Today, New Life Agency ... expensive fertility medications. ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ... ...
Breaking Medicine Technology:
(Date:9/25/2017)... , ... September 25, 2017 , ... ... Arizona State University student Ashlea Grabau. The $1000 student scholarship is awarded each ... scholarship was awarded to Ashlea Grabau who is a medical student at Arizona ...
(Date:9/25/2017)... FL (PRWEB) , ... September 25, 2017 , ... ... Inc. announced today that they have teamed up to deliver Netmail’s Hadron Data ... HIPAA/HITRUST compliant Azure Cloud. Netmail will be demoing their Hadron solution in a ...
(Date:9/25/2017)... ... September 25, 2017 , ... Just ask anyone old enough to remember what ... headgear so wired up and containing so much metal that jokes about radio reception ... its treatments can barely be observed. As a result, it’s now a billion-dollar industry ...
(Date:9/25/2017)... N.J. (PRWEB) , ... September 25, 2017 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... on the development and validation of bioassays at two upcoming conferences. , At ...
(Date:9/25/2017)... ... September 25, 2017 , ... International Water Advocate Sharon Kleyne ... Hour Power of Water, Global Climate Change and Your Health on VoiceAmerica sponsored ... a once-every-four-years series of events to a personal, daily Health Olympics. “Wouldn’t it ...
Breaking Medicine News(10 mins):